<DOC>
	<DOC>NCT00856544</DOC>
	<brief_summary>This Phase 3 study is intended to provide evidence that CP-690,550 dosed 5 mg BID and 10 mg BID is safe and effective when used in combination with a variety of traditional disease modifying antirheumatic drugs in adult patients with rheumatoid arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in the Phase 2 rheumatoid arthritis studies.</brief_summary>
	<brief_title>A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>The patient has a diagnosis of Rheumatoid Arthritis based on the American College of Rheumatology (ACR) 1987 Revised Criteria. The patient has active disease as defined by both &gt;=4 tender or painful joints on motion and &gt;= 4 joints swollen; and either an erythrocyte sedimentation rate (ESR) &gt; 28 mm or a Creactive protein (CRP) concentration &gt; 7 mg/dL. Patient had an inadequate response to at least one disease modifying antirheumatic drug (traditional or biologic) due to lack of efficacy or toxicity. Patient must remain on at least one background traditional disease modifying antirheumatic drug. No evidence of inadequately treated latent or active infection with Mycobacterium tuberculosis. Blood dyscrasias including confirmed: Hemoglobin &lt;9 g/dL or Hematocrit &lt;30%; White blood cell count &lt;3.0 x 109/L; Absolute neutrophil count &lt;1.2 x 109/L; Platelet count &lt;100 x 109/L. History of any other rheumatic autoimmune disease other than Sjogren's syndrome. No malignancy or history of malignancy. History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Arthritis</keyword>
	<keyword>Rheumatoid</keyword>
	<keyword>Antirheumatic Agents</keyword>
	<keyword>Clinical Trial</keyword>
</DOC>